ProteoTech and Tasly Pharmaceuticals announce Alzheimer’s disease drug development agreement for Exebryl-1

U.S.-Chinese collaboration revolves around potential disease-modifying Alzheimer’s treatment that targets beta- amyloid and tau protein

Jeffrey Bouley
KIRKLAND, Wash.—ProteoTech Inc. and Tianjin, China-based Tasly Pharmaceutical Co. Ltd.  have announced an agreement to co-develop ProteoTech's novel small-molecule therapeutic, Exebryl-1, for the treatment of mild-to-moderate Alzheimer's disease. In research work so far, Exebryl-1 has been shown to inhibit beta-amyloid protein aggregate formation in the brain, as well as disaggregate amyloid plaques that are already present.  The drug has also shown specificity against tau protein aggregates and may be the first therapeutic targeting both the beta-amyloid and tau protein that are associated with this disease.

The collaboration will focus on moving the clinical development of this drug though the regulatory process in China and the United States.  Although the companies did not disclose specific financial terms of the deal, the deal does call for an upfront payment, development costs and research funding to ProteoTech, according to Manuel Menendez, managing partner of Nobel Pacific, who acted as an advisor to both companies. Tasly will gain rights for Exebryl-1 for China and ProteoTech will retain rights for the United States and the rest of the world.

"We are very happy with this opportunity to work with the team at ProteoTech and we feel that Exebryl-1 will become a very important medication in China against the growing epidemic of Alzheimer's disease" says Dr. Henry Sun, vice president of Tasly Group and president of Tasly Pharmaceuticals Inc.

"The opportunity for this collaboration with a major international pharmaceutical company is very exciting for us," adds Steve Runnels, CEO of ProteoTech CEO. "We are very fortunate to have Tasly as a partner and their experience in drug development, especially in China, provides an opportunity to accelerate Exebryl-1 through clinical development. We look forward to a successful Exebryl-1 collaboration with Tasly and the potential development of other promising technologies in our pipeline as well."

ProteoTech is a private drug development company in Kirkland, Wash., that is focused on targeting amyloid diseases. In addition to Exebryl-1 for Alzheimer's disease treatment, the company is also in late-stage preclinical development of Synuclere for the treatment of Parkinson's disease, Systebryl for the treatment of systemic amyloidosis, and a novel small peptide called PeptiClere for the treatment of Alzheimer's disease.

Tasly was founded in May 1994 in Tianjin, China, and with the pharmaceutical industry as its centerpoint, Tasly reportedly has become a leading group of high-technology companies whose scope of business includes ethical pharmaceutical and biological medications, healthcare products and functional foods.
 

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Front Cover

Latest Issue  

• Volume 18 • Issue 12 • December 2022/January 2023

December 2022/January 2023

December 2022/January 2023 issue